Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer

British Journal of Biomedical Science

Volumn 67, Issue 3, 2010, Pages 109-112

  El Melegy, Nagla T ^a   Aboulella, H A ^a   Abul Fadl, A M ^a   Mohamed, N A ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Cathepsin D; N Acetylneuraminic acid; Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

CATHEPSIN D; N ACETYLNEURAMINIC ACID; PROSTATE SPECIFIC ANTIGEN; SIALIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE MARKER; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SERUM; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; UNIVERSITY HOSPITAL;

EID: 77957001036     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2010.11730306     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Matthew BG, Alan WP et al. Prostate cancer tumor markers. In: Kavoussi LR, Novick AC, Partin AW, Peters CA eds Campbell- Walsh Urology. 9th edn. Philiadephia: Saunders, 2007: Ch 93, 2896-910.
3. Margreiter M, Stangelberger A, Valimberti E, Herwig R, Djavan B. Biomarkers for early prostate cancer detection. Minerva Urol Nefrol 2008; 60: 51-60.
4. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 112-20. (Pubitemid 351676597)
5. Nogueira L, Corradi R, Eastham J. Prostatic specific antigen for prostate cancer detection. Int Braz J Urol 2009; 35: 521-31.
6. Berbec H, Paszkowska A, Siwek B, Gradziel K Gybulski M. Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia. Eur J Gyneacol Oncol 1999; 20: 389-92.
7. Cherry J, Mordente J, Chapman J et al. Analysis of cathepsin D forms and their clinical implications in human prostate cancer. J Urol 1998; 160: 2223-8.
8. Vashi A, Wojno K, Henricks W. Determination of the 'reflex range' and appropriate cutpoints for percent free-PSA in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27.
9. Kuriyama K, Wang M, Papsidero L et al. Quantification of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40: 4658-62. (Pubitemid 11199734)
10. Plucinsky M, Riley W, Prorok K, Ahladeff J. Total and lipid- associated sialic acid levels in cancer patients with different primary sites and different degrees of metastatic involvements. Cancer 1986; 58: 2680-5.
11. Kuhn SH, de Kock MA. A preliminary study of elevated alkaline phosphatase and cathepsin in bronchial aspirates of patients with lung cancer and bronchitis. Chest 1975; 68: 326-30.
12. Babaian RJ, Miyashita H, Evans RB, Ramirez EI. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol. 1992; 147 (3 Pt 2): 837-40.
13. Ellis W, Etzioni R, Vessella R, Chengcheng H, Goodman G. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J Urol 2001; 166: 93-9.
14. Martinez L, Tabernero A, Contreras T et al. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/mL. Eur Urol 2000; 37: 289-96.
15. Espana F, Royu M, Enguidanos M et al. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol 1998; 160: 2081-8. (Pubitemid 128703619)
16. Basso D, Fogar P, Piva M et al. Total PSA, free PSA/total PSA ratio and molecular PSA detection in prostate cancer: Which is clinically effective and when? Urology 2000; 55: 710-5.
17. Hara N, Kitamura Y, Saito T, Komatsubara S. Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. Asian J Androl 2006; 8: 429-34.
18. Mungan AG, Erol B, Akduman B et al. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population. Clin Chem Lab Med 2007; 45: 912-6.
19. Masters J, Keegan P, Hildreth A, Greene D. Free/total serum prostate-specific antigen ratio: how helpful is it in detecting prostate cancer? Br J Urol 1998; 81: 419-23.
20. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67: 762-8.
21. de la Taille A, Houlgatte A, Houdelette P, Goluboff ET, Berlizot P, Ricordel I. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays. Br J Urol 1998; 82: 389-92.
22. Erbil K, Sabri E, Zincke H, Jones JD. Significance of serum protein and lipid-bound sialic acid as a marker for gastrointestinal malignancies. Cancer 1986; 57: 1389-94. (Pubitemid 16136761)
23. Hobarth K, Hofbauer J, Fang-Kircher S. Plasma sialic acid in patients with prostate cancer. Br J Urol 1993; 72: 621-4.
24. Harvey H, Lipton A, White D, Davidson E. Glyco-proteins and human cancer: II Correlations between circulating level and disease status. Cancer 1981; 47: 324-7. (Pubitemid 11179329)
25. Romppanen J, Haapalainen T, Punnonen K, Penttila I. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer. Anticancer Res 2002; 22: 415-20.
26. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005; 52: 1-9. (Pubitemid 40502564)
27. Miyake H, Hara I, Eto H. Prediction of the extent of prostate cancer by the combined use of systematic biopsy and serum level of cathepsin D. Int J Urol 2003; 10: 196-200.
28. Mordente J, Choudhury M, Tazaki H, Mallouh C, Konno S. Hydrolysis of androgen receptor by cathepsin D: its biological significance in human prostate cancer. Br J Urol 1998; 82: 431-5.
29. Gómez Dìaz ME, Ruibal-Morell A, Abascal Garcìa R. Proteases and prostatic disease: cytosolic cathepsin D (in Spanish). Arch Esp Urol 2001; 54: 101-7.
30. Hara I, Miyake H, Yamanaka K, Hara S, Kamidono S. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Oncol Rep 2002; 9 (6): 1379-83.